Stonebridge Capital Advisors’s Biogen BIIB Stock Holding History

Stonebridge Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-60	Closed	-$15.4K	–	278
2023 Q3	$15.4K	Sell	60 -29	-33%	-$7.76K	﹤0.01%	535
2023 Q2	$25.4K	Buy	89 +29	+48%	+$8.63K	﹤0.01%	472
2023 Q1	$16.7K	Sell	60 -10	-14%	-$2.77K	﹤0.01%	535
2022 Q4	$19.4K	Hold	70	–	–	﹤0.01%	498
2022 Q3	$19K	Hold	70	–	–	﹤0.01%	475
2022 Q2	$14K	Hold	70	–	–	﹤0.01%	538
2022 Q1	$15K	Sell	70 -2	-3%	-$435	﹤0.01%	582
2021 Q4	$17K	Sell	72 -12	-14%	-$3.08K	﹤0.01%	532
2021 Q3	$24K	Hold	84	–	–	﹤0.01%	455
2021 Q2	$29K	Buy	84 +14	+20%	+$4.24K	﹤0.01%	428
2021 Q1	$20K	Buy	+70	New	+$18.9K	﹤0.01%	500
2020 Q3	–	Sell	-10	Closed	-$3K	–	237
2020 Q2	$3K	Hold	10	–	–	﹤0.01%	608
2020 Q1	$3K	Hold	10	–	–	﹤0.01%	595
2019 Q4	$3K	Hold	10	–	–	﹤0.01%	692
2019 Q3	$2K	Hold	10	–	–	﹤0.01%	708
2019 Q2	$2K	Buy	+10	New	+$2.31K	﹤0.01%	759

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Stonebridge Capital Advisors's BIIB Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Biogen (BIIB) in Q4 2023, closing a stake of 60 shares — an estimated $15.4K sold.

Stonebridge Capital Advisors first reported a position in BIIB in Q2 2019 and held it in 16 quarters. The position peaked at $29K in Q2 2021. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 60 Biogen shares in Q4 2023, an estimated $15.4K.
Stonebridge Capital Advisors first reported a position in Biogen in Q2 2019 and held it in 16 quarters.
Stonebridge Capital Advisors's Biogen position peaked at $29K in Q2 2021.
1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.